Rational Use of New and Emerging Agents for Hepatitis Delta Virus

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:

• Assembly inhibitors (eg, lonafarnib)
• Entry inhibitors (eg, bulevirtide)
• Interferon lambda
• Nucleic acid polymers
• Small interfering RNA (siRNA) agents

Presenters: 

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany

Cihan Yurdadin, MD
Professor and Chief
 Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Link to full program:
https://bit.ly/365VUlG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.